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A B S T R A C T
Objective: To search for predictors of metformin response in women with polycystic ovary syndrome
(PCOS) through a detailed analysis of clinical and laboratory parameters.
Study design: We designed a prospective study to investigate clinical and laboratory parameters to
search for predictors of metformin response in women with PCOS. A total of 53 PCOS patients were given
metformin 850 mg twice a day for 6 months, after which patients were classiﬁed as responders or non-
responders. Parameters analyzed for comparison between the two groups were: plasma fasting insulin
glucose/insulin ratio; oral glucose tolerance test (OGTT) with insulin (120 min); HOMA and QUICKI tests;
total cholesterol and fractions, triglycerides; LH, FSH, estradiol, progesterone, testosterone, androstene-
dione, 17-OH progesterone, and DHEAS.
Results: From all patients, 30 (56.6%) were responders and 23 (43.3%) were non-responders. Multinomial
analysis showed that the positive response to metformin was associated with higher levels of basal LH
(p = 0.038) and lower levels of high-density lipoprotein cholesterol (HDL-C) (p = 0.015).
Conclusion: In weight-matched PCOS subjects, laboratory markers might predict the metformin
response. Higher levels of basal LH and lower levels of HDL-C are correlated with a positive response to
metformin treatment in PCOS subjects.
 2011 Elsevier Ireland Ltd. 
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Polycystic ovary syndrome (PCOS) is a complex endocrine
disease characterized by hyperandrogenism and anovulation.
Insulin resistance plays a major role in its pathophysiology and
affects both obese and non-obese women, and is thought to be
linked to several metabolic changes associated with the syndrome
[1,2]. One therapy used to reduce the insulin resistance is
metformin, which is a biguanide used as an insulin-sensitizing
agent [3,4]. However, not all subjects respond to metformin
treatment the same way. A group of patients, usually called non-
responders, do not experience the beneﬁts of the treatment with
this drug for unknown reasons [5]. To date, predictors of clinical
response to metformin therapy have been analyzed in a few
studies with conﬂicting results [6–8]. The aim of this study was to* Corresponding author at: Disciplina de Ginecologia da Universidade de Sa˜o
Paulo, Al. Joaquim, Eugenio de Lima, 1481 ap. 42, Sa˜o Paulo, SA 01403-003, Brazil.
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Open access under the Elsevier OA license. evaluate parameters to predict different types of response and to
establish criteria for metformin use.
2. Material and methods
2.1. Subjects
This was a prospective, open-labeled, single center study to
investigate predictor factors of metformin response in women with
PCOS. The subjects were referred to the Division of Gynecologic
Endocrinology for hirsutism evaluation. Fifty-three PCOS patients
aged 15–40 years (mean 25.2  5.9) with mean body mass index
29.5  6.9 kg/m2 (17.1–51.9) were enrolled for this study. All of them
had menstrual disturbances. More than half (52.8%) presented with
amenorrhea more than 3, 45.3% had oligomenorrhea, and 1.9% had
hypermenorrhagia. The diagnosis of PCOS was done according to the
Androgen Excess Society (2006) criteria [9]. As a routine, the use of
drugs, tobacco and physical activity were noted. All subjects were
submitted to a synthetic ACTH test, and other causes of hyperan-
drogenism and anovulation, namely Cushing’s syndrome, late-onset
21-hydroxylase deﬁciency, thyroid dysfunction, hyperprolactinemia
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tests. No subject had other diseases or had taken medications for at
least 6 months prior to the study. The Institutional Review Board of the
Faculdade de Medicina da Universidade de Sa˜o Paulo, Sa˜o Paulo, Brazil,
approved the study.
2.2. Clinical and laboratorial parameters
Body mass index (BMI) was calculated with the formula weight
(kg)/height (m2). Hirsutism was deﬁned by the presence of
excessive body hair distributed in an androgen-dependent pattern,
with a modiﬁed Ferriman and Gallwey score 8, and the presence
of acne was noted at each visit [10]. An oral glucose tolerance test
(OGTT) was performed between 7.30 and 8.30 am. After an
overnight fast, blood samples were obtained through an intrave-
nous catheter placed in the forearm for the determination of
fasting blood glucose, insulin, gonadotropins, estradiol (E2), total
testosterone (T) and dehydroepiandrosterone sulfate (DHEAS),
triglycerides and total cholesterol and its fractions. A 75 g of
glucose load was given, and blood collected 30, 60, 90 and 120 min
thereafter, for determination of glucose and insulin. Samples were
considered only when progesterone concentration in the basal
sample was less than 1.0 ng/mL. Blood pressure (BP) was measured
with a mercury sphygmomanometer with rubber sleeves of
different sizes according to the arm circumference of the woman.
Polycystic appearance of ovaries on transvaginal sonography was
deﬁned according to the Rotterdam Consensus Guidelines [11].
Subjects with abnormal response to synthetic ACTH were excluded
from this study and referred for appropriate treatment. We
included only patients with HOMA-IR >2.7.
2.3. Metformin treatment
Patients took metformin 850 mg orally, twice a day for 6
months. The initial dose was progressively increased for two weeks
in order to avoid common side effects such as nausea and diarrhea.
After the end of the treatment period, the patients were classiﬁed
as responders (group A) and non-responders (group B). Responders
were deﬁned as subjects who had amelioration of their menstrual
frequency (cycles of 25–35 days). Also, we considered at least two
menses during the study for patients with amenorrhea. Non-
responders were those who did not meet these criteria [3,12–15].
Compliance was assured by checking the empty blisters on the
treatment packs at each visit and all patients were oriented to keep
menstrual logs using diary cards. We excluded patients who used
<80% of metformin tablets.
2.4. Laboratory parameters analyzed for prediction of response
The cutoff of the parameters analyzed as predictors was based
on standard values of our laboratory (fasting insulin, SHBG,
gonadotropins, and androgens), and the literature (glucose/insulin
ratio LH/FSH ratio, fasting glucose, high-density lipoprotein (HDL)
and triglycerides). Insulin sensitivity was assessed using Homeo-
static Model Assessment (HOMA-IR) [16], and the values
were those adopted in our laboratory based on the Brazilian
population [17].
2.5. Methods
Plasma glucose concentration was determined by a glucose
oxidase method. All lipid determinations were measured directly
on plasma samples. Plasma total cholesterol and triglycerides were
determined using enzymatic methods (Roche Laboratories). HDL-
cholesterol (HDL-C) was performed by the same method as for
cholesterol and low-density lipoprotein cholesterol (LDL-C) wasestimated as previously described [17]. For hormone assays, blood
samples were processed by centrifuge, and serum was stored at
20 8C until assayed. Progesterone, testosterone and androstene-
dione were measured by immunoﬂuorometric assay (Wallac,
Finland), insulin, LH and FSH were measured by immunoﬂuoro-
metric assay (Wallac, Finland) and DHEAS was measured by
radioimmunoassay (Cisbio International, France, and DSL, TX,
USA). All the assays were performed in duplicate and the intra-
assay and inter-assay coefﬁcients of variation did not exceed 10%
and 15%, respectively.
2.6. Statistical analysis
For statistical purposes, metformin response was classiﬁed as
positive or negative. The study considered age, BMI, LH, E2,
testosterone, androstenedione, DHEAS, 17OHP, fasting glucose,
SHBG, HDL-C and triglycerides as independent or predictive
variables to forecast treatment results. Basal values were used as
references to access relative change. Multinomial logistic regres-
sion [18] was used with the variable and covariate variables listed
above. We used transformed variables as a percentual variation of
each one of them in relation to pretreatment values. Pearson’s Chi-
square statistic test was used to test variables’ responses to the
treatment [19]. To assess the impact of the treatment on weight,
we used the paired t-test (95% conﬁdence intervals (CIs) [20]. A p
value <0.05 was considered to be signiﬁcant, and the results are
presented as the mean  SE.
3. Results
3.1. Clinical features
Before treatment, groups were homogeneous regarding age,
menstrual history, BMI, presence of clinical signs of hyperandro-
genism, serum androgen levels and insulin resistance. Among all
subjects (n = 53), 11 (20.8%) had normal weight (BMI < 25 kg/m2),
14 (26.4%) were overweight (BMI = 25–29.9 kg/m2), 21 (39.6%)
were obese (BMI = 30–39.9 kg/m2) and 7 (13.2%) were morbidly
obese (BMI  40 kg/m2). As shown in Table 1, there were no
signiﬁcant changes in hirsutism score, BMI or weight. Blood
pressure also did not change signiﬁcantly (data not shown).
3.2. Metformin treatment
Thirty patients (56.6%) were considered responders and 23
(43.3%) non-responders. In the responders group, three patients
became pregnant within 6 months of treatment (2 patients in the
second month). Over one-third (37.5%) of the patients presented
some degree of side effects, mainly nausea, vomiting, diarrhea and
abdominal cramps. Most of these occurred at the beginning of the
treatment and usually there was a tendency to remission after one
month. Only two subjects abandoned the study due the severity of
the side effects. After 6 months of treatment, 65.3% of the subjects
presented some degree of weight loss and 34.7% showed an
increment or stability in weight. There were no differences,
however, between groups (responders and non-responders)
regarding weight loss (p = 0.461), ruling out the possibility of
weight inﬂuence on metformin response. There was no change in
hirsutism score. Response to synthetic ACTH and ultrasonography
did not show any statistical difference between groups. The
responder group presented an improvement of menstrual abnor-
malities, and 21 women (70%) returned to near-regular menstrual
cycles (intervals of 25–35 days), six (20%) menstruated every 45
days and three (10%) became pregnant during metformin
treatment. In the non-responder group, there was a higher rate
of amenorrhea (69.6% vs 43.3%, p = 0.137).
Fig. 1. Levels of testosterone and estradiol at baseline and after six months of
treatment with metformin in the two groups of response.
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In order to search for possible predictors of metformin
response, we tested a series of known parameters and tried to
establish a correlation between them and a positive response to
the drug. Association of the pretreatment condition with metfor-
min response was performed using a Multinomial Logistic
Regression Analysis considering the values of each parameter as
an independent or a predictive variable and the response to the
treatment itself, as a dependent variable. The majority did not
correlate to metformin response: namely SHBG < 19 mmol/L
(p = 0.188), BMI > 27 kg/m2 (p = 0.157), triglycerides > 150 mg/
dL (p = 0.353), LH/FSH  2 (p = 0.366), T > 86 ng/dL (p = 0.410),
A4 > 3.1 ng/mL (p = 0.845), 17OH-P > 1.0 ng/mL (p = 0.678), basal
insulin levels (p = 0.14), and glucose/insulin ratio (p = 0.39).
We found that high LH and low HDL-C were predictors of
metformin positive response. The majority of subjects (66.7%) with
a positive response to metformin presented higher levels of basal
LH (>12 mUI/mL, p = 0.03). On the other hand, when LH levels
were below that cut-off, 50% were responders and 50% non-
responders (Fig. 2). LH levels cut-off was established in our central
laboratory according to the manufacturer’s parameters (DSL, TX,
USA). Furthermore, most of the responders also presented low
levels of HDL-C (<50 mg/dL, p = 0.038) and higher levels of DHEA-
S, 64.7% and 80%, respectively. Patients with basal high DHEAS
levels (>3900 ng/mL) presented a tendency to statistical signiﬁ-
cance (p = 0.054), and might reﬂect a tissue-speciﬁc sensitivity to
metformin. The p-value came from the regression adjustment and
it is associated with the signiﬁcance of predictor variable to explain
the outcome (variable response).
Table 1 shows the results of laboratory parameters analyzed
and the comparison between the baseline and post-treatment
values. Mean levels of testosterone, LH and estradiol were
signiﬁcantly different after 6 months of treatment in both groups,
responders and non-responders.
Fig. 1 shows the mean levels of testosterone and estradiol in
both groups before and after treatment. Testosterone levels were
lower solely in the responders group (Fig. 1), reﬂecting metformin
action and efﬁcacy in terms of diminishing hyperandrogenemia.
Conversely, estradiol levels rose signiﬁcantly in the responders
group, which clinically is related to the improvement of theTable 1
Laboratorial and clinical parameters at the baseline and after six months of treatment
Parameters Responders 
Before After 6 month
FSH (mUI/mL) 5.07  1.4 4.32  1.89
LH (mUI/mL) 11.06  5.1 7.07  3.42
Estradiol (ng/mL) 57.3  32.4 86.2  80.7 
Testosterone (ng/mL) 113.9  46.9 68.8  32.8 
Androstenedione (ng/mL) 3.06  1.52 2.54  1.80
DHEA-S (ng/mL) 2245.4  1482.5 2225.0  1443
17-OHP (ng/mL) 1.17  0.88 0.75  0.45
Fasting glucose (mg/dL) 95.0  15.1 97.7  38.8 
SHBG (mmol/L) 25.9  11.5 23.3  11.9 
HDL-C (mg/dL) 41.0  8.5 43.5  9.7 
Triglycerides (mg/dL) 150.0  107.5 126.6  57.6 
Age (year) 25.0  6.3 – 
Weight (kg) 75.7  19.2 77.1  17.6 
BMI (kg/m2) 30.9  7.0 30.0  6.9 
AC (cm) 92.8  14.6 – 
Hirsutism score 14.1  7.3 11.5  5.4 
Acne (%) 58.6 55.2 
p value shows signiﬁcance between basal and post treatment as deﬁned by Pearson’s Ch
abdominal circumference; A4, androstenedione; E2, estradiol; DHEA-S, dehydroepian
polycystic ovary syndrome; T, testosterone.
a p = 0.02.
b p = 0.005.
c p = 0.04.menstrual cycle in the responders group. In this sense, the more
favorable hormonal proﬁle in that group conﬁrms that in those
subjects metformin was able to tackle the main features of PCOS,
hyperandrogenism and menstrual irregularities.
4. Comments
One important aspect of the use of metformin is responsiveness,
i.e., clinical efﬁcacy [21]. Here we showed that, in PCOS subjects
using metformin, there are differences in drug response regarding
clinical ﬁndings and testosterone levels and that positive response
was associated with basal higher levels of LH and lower levels of
HDL-C.
The ﬁrst predictor factor we found was the high levels of LH.
PCOS patients with high levels of basal LH are more likely to
respond positively to metformin. PCOS subjects may present
neuroendocrine abnormalities, but the relationship of gonadotro-
pin secretion, PCOS phenotype and metformin is complex and not
well understood. An increased LH pulse frequency in PCOS women,
independent of BMI or adiposity, is well established [22,23].
Normal weight PCOS women present higher frequency and with metformin.
Non-responders p
s Before After 6 months
 4.77  1.17 4.83  2.11 NS
 8.83  4.17 10.9  5.96 a
55.6  25.5 46.2  14.1 b
103.9  31.6 87.0  30.5 c
 3.12  1.43 3.67  1.33 NS
.4 2028.9  1241.7 2447.3  1225.6 NS
 1.09  0.79 1.42  0.67 NS
92.2  14.8 90.0  26.8 NS
29.6  14.6 20.5  5.93
48.0  12.5 64.5  37.3
113.1  45.8 95.0  26.9
25.5  4.5 – –
83.7  26.3 76.0  18.3 NS
33.6  6.9 31.8  8.4 NS
96.4  18.6 – –
13.3  7.7 11.4  7.3 NS
36.4 31.8 NS
i-square test and pared t-test (BMI). NS, not signiﬁcant; BMI, body mass index; AC,
drostenedione sulfate; 17-OHP, 17-hydroxyprogesterone; P, progesterone; PCOS,
Fig. 2. Percentage of positive response to metformin according to the presence of
high levels of LH at the baseline related to metformin response.
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levels. In contrast, in obese PCOS, LH pulse amplitude and the LH
response to GnRH is attenuated in parallel with the degree of
obesity, and the accelerated pulse frequency alone accounts for the
high mean levels of LH increase [22]. In this sense, the fact that
both groups, responders and nonresponders, have similar BMI at
the baseline, may exclude an additional confusing factor.
Additionally, the responders group presented a signiﬁcant fall
in LH levels during the treatment period. Most, but not all, studies
using metformin to treat PCOS showed an impact on LH secretion
in conjunction with insulin suppression, suggesting an inﬂuence of
insulin on LH secretion [24]. In a study that showed that the use of
metformin reduces the LH pulse amplitude in non-obese PCOS
subjects, the authors proposed that the reduction in LH pulse
amplitude was result of a modulation exerted by metformin-
induced changes in ovarian function and/or in the tissue sensitivity
to insulin and growth factors on GnRH discharge [25]. Recently,
another study showed that prenatal androgen programs the
activity of GnRH neurons and favors high LH secretion in mice.
Metformin treatment is able to revert this effect through the
activation of AMP-activated protein kinase (AMPK) in the
hypothalamus [26].
One possible explanation for our ﬁndings is that the responders
group constitutes a speciﬁc genetic subset of PCOS subjects, more
sensitive to metformin at the gonadotroph level. Another
hypothesis is that the effect of metformin response was mediated
through insulin. Insulin increases basal and GnRH-stimulated LH
and FSH secretion from cultured rat pituitary cells in vitro [27,28].
Several studies suggest that the abnormal LH production in PCOS
may be due insulin dysregulation at the level of the gonadotroph
[29]. Furthermore, a recent study using mice with a pituitary-
speciﬁc knockout of the insulin receptor showed that the
gonadotroph maintains insulin sensitivity in a setting of peripheral
insulin resistance [30]. Interestingly, metformin (an insulin-
sensitizer drug) showed better efﬁcacy in those patients with
impaired gonadotropin production, suggesting that insulin modu-
lation at pituitary level might account for the response. Levels of
testosterone dropped signiﬁcantly and estrogen rose, deﬁning a
more favorable hormonal scenario that was reﬂected clinically.
The second predictor was the lower level of HDL-C. Subjects
with HDL-C lower than 50 mg/dL responded better to metformin
within 6 months of treatment. Similarly to PCOS, metabolic
syndrome is associated with insulin resistance, low levels of HDL-C
and hypertriglyceridemia [31]. Some authors contend that PCOS
and metabolic syndrome might be two different degrees of the
same basal condition [32,33]. Insulin resistance is highly related to
lower levels of HDL-C but the exact mechanism of this relationship
is still unclear. It seems that HDL modulates glucose metabolism
through activation of the key metabolic regulatory enzyme, AMP-
activated protein kinase (AMPK), in skeletal muscle. Similarly tothe metformin action in the gonadotroph, recent studies have
proposed a tissue-speciﬁc effect of this drug also in the muscle of
insulin resistant subjects. Thus, lower HDL-C might reﬂect the
extension of the insulin resistance role in the responders group.
In conclusion, we suggest that laboratory markers, namely, high
levels of LH and low levels of HDL-C, might be useful predictors of
metformin response in PCOS subjects in a real clinical setting.
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